Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTAFR | P25105 | 2/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1373861 | 1.00 | PTAFR (0.41) | PTAFRAKT1MTNR1AMTNR1BHPGD | |
| SCHEMBL6692316 | 0.86 | AKT1 (0.42) | PTAFRAKT1MTNR1AMTNR1BHPGD | |
| SCHEMBL6692313 | 0.86 | AKT1 (0.42) | PTAFRAKT1MTNR1AMTNR1BHPGD | |
| SCHEMBL133925 | 0.78 | AKT1 (0.41) | AKT1MTNR1AMTNR1BCYP3A4MAPT | |
| SCHEMBL133924 | 0.78 | AKT1 (0.41) | AKT1MTNR1AMTNR1BCYP3A4MAPT | |
| Propionic Acid SCHEMBL1525114 | 0.77 | CES2 (0.42) | AKT1MTNR1AMTNR1BHPGDCYP3A4 | |
| Propionic Acid SCHEMBL1525115 | 0.77 | CES2 (0.42) | AKT1MTNR1AMTNR1BHPGDCYP3A4 | |
| SCHEMBL1232561 | 0.76 | HDAC3 (0.45) | PTAFRAKT1MTNR1AMTNR1BHPGD | |
| SCHEMBL1931541 | 0.76 | AKT1 (0.40) | AKT1MTNR1AMTNR1BCYP3A4MAPT | |
| SCHEMBL1931543 | 0.76 | AKT1 (0.40) | AKT1MTNR1AMTNR1BCYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180852-A1 | TREATMENT FOR MALIGNANT PLEURAL EFFUSION IN HUMANS | SIGNPATH PHARMA, INC. | 2024-06-06 | — | — | US | claimed |
| US-20200360300-A1 | Suppression of Cytokine Release and Cytokine Storm | SIGNPATH PHARMA, INC. | 2020-11-19 | — | — | US | claimed |
| US-10739353-B2 | Suppression of cytokine release and cytokine storm | SIGNPATH PHARMA, INC. (US) | 2020-08-11 | — | — | US | claimed |
| US-20190105287-A1 | Liposomal Curcumin for Treatment of Cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-04-11 | — | — | US | claimed |
| US-20180318217-A1 | Liposomal Curcumin for Treatment of Diseases | SIGNPATH PHARMA INC. | 2018-11-08 | — | — | US | claimed |
| US-10004687-B2 | Liposomal curcumin for treatment of diseases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-06-26 | — | — | US | claimed |
| US-20160287532-A1 | CURCUMIN FOR TREATING INTERVERTEBRAL DISC DISEASE | SIGNPATH PHARMA INC. | 2016-10-06 | — | — | US | claimed |
| US-20160193159-A1 | LIPOSOMAL CURCUMIN FOR TREATMENT OF CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2016-07-07 | — | — | US | claimed |
| US-20160184330-A1 | Suppression of Cytokine Release and Cytokine Storm | AVANTI POLAR LIPIDS, INC. | 2016-06-30 | — | — | US | claimed |
| US-9283185-B2 | Liposomal curcumin for treatment of cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-03-15 | — | — | US | claimed |
| US-20140322303-A1 | LIPOSOMAL CURCUMIN FOR TREATMENT OF DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-10-30 | — | — | US | claimed |
| US-8784881-B2 | Liposomal curcumin for treatment of diseases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-07-22 | — | — | US | claimed |
| US-20110287085-A1 | LIPOSOMAL CURCUMIN FOR TREATMENT OF CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-11-24 | — | — | US | claimed |
| US-20100316631-A1 | Water Soluble Curcumin-Based Compounds | THE UAB RESEARCH FOUNDATION (US) | 2010-12-16 | — | — | US | claimed |
| US-20080138400-A1 | Curcumin analog or metabolite microencapsulated by a polyethylene glycolated liposome of dimyristoyl phosphatidylcholine, cholesterol, and dimyristoyl phsphatidylethanolamine; anticarcinogenic and antiproliferative agents; parenteral colloidal drug delivery system providing improved bioavailability | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-06-12 | — | — | US | claimed |
| US-20080103213-A1 | LIPOSOMAL CURCUMIN FOR TREATMENT OF NEUROFIBROMATOSIS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-05-01 | — | — | US | claimed |
| US-20060067998-A1 | Curcumin analog or metabolite microencapsulated by a polyethylene glycolated liposome of dimyristoyl phosphatidylcholine, cholesterol, and dimyristoyl phsphatidylethanolamine; parenteral colloidal drug delivery system providing improved bioavailability | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-03-30 | — | — | US | claimed |
| US-20260144750-A1 | Dosing Regimens for Treatment of Glioblastoma | SIGNPATH PHARMA INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20080076821-A1 | INTRANASALLY ADMINISTERING CURCUMIN PRODRUGS TO THE BRAIN TO TREAT ALZHEIMER'S DISEASE | DePuy Synthes Products, Inc. | 2008-03-27 | — | — | US | disclosed |
| US-20060067998-A1 | Curcumin analog or metabolite microencapsulated by a polyethylene glycolated liposome of dimyristoyl phosphatidylcholine, cholesterol, and dimyristoyl phsphatidylethanolamine; parenteral colloidal drug delivery system providing improved bioavailability | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060067998-A1 | Curcumin analog or metabolite microencapsulated by a polyethylene glycolated liposome of dimyristoyl phosphatidylcholine, cholesterol, and dimyristoyl phsphatidylethanolamine; parenteral colloidal drug delivery system providing improved bioavailability | PNLIP, SGMS2, SGMS1 | PTAFR 1509/4885AKT1 1334/4885MTNR1A 1070/4885 |
| US-20160193159-A1 | LIPOSOMAL CURCUMIN FOR TREATMENT OF CANCER | PNLIP, BRCA1, IAPP | PTAFR 3053/4885AKT1 2278/4885MTNR1A 845/4885 |
| US-20160184330-A1 | Suppression of Cytokine Release and Cytokine Storm | TNF, IL2, IL6 | PTAFR 2280/4885AKT1 838/4885MTNR1A 2567/4885 |
| US-20140322303-A1 | LIPOSOMAL CURCUMIN FOR TREATMENT OF DISEASES | LIPA, LPCAT3, LCLAT1 | PTAFR 3986/4885AKT1 2899/4885MTNR1A 2380/4885 |
| US-20190105287-A1 | Liposomal Curcumin for Treatment of Cancer | PNLIP, BRCA1, IAPP | PTAFR 3053/4885AKT1 2278/4885MTNR1A 845/4885 |
| US-20240180852-A1 | TREATMENT FOR MALIGNANT PLEURAL EFFUSION IN HUMANS | MTDH, PLEC, LPCAT3 | PTAFR 680/4885AKT1 3779/4885MTNR1A 1993/4885 |
| US-20200360300-A1 | Suppression of Cytokine Release and Cytokine Storm | TNF, IL6, IL1B | PTAFR 2156/4885AKT1 893/4885MTNR1A 2160/4885 |
| US-20160287532-A1 | CURCUMIN FOR TREATING INTERVERTEBRAL DISC DISEASE | TRPV1, ORAI1, TRPA1 | PTAFR 3774/4885AKT1 2125/4885MTNR1A 1929/4885 |
| US-20110287085-A1 | LIPOSOMAL CURCUMIN FOR TREATMENT OF CANCER | PNLIP, BRCA1, IAPP | PTAFR 3053/4885AKT1 2278/4885MTNR1A 845/4885 |
| US-20260144750-A1 | Dosing Regimens for Treatment of Glioblastoma | CCND1, CCND2, CCNE2 | PTAFR 1830/4885AKT1 136/4885MTNR1A 4355/4885 |
| US-20180318217-A1 | Liposomal Curcumin for Treatment of Diseases | LIPA, LPCAT3, LCLAT1 | PTAFR 3986/4885AKT1 2899/4885MTNR1A 2380/4885 |
| US-20080138400-A1 | Curcumin analog or metabolite microencapsulated by a polyethylene glycolated liposome of dimyristoyl phosphatidylcholine, cholesterol, and dimyristoyl phsphatidylethanolamine; anticarcinogenic and antiproliferative agents; parenteral colloidal drug delivery system providing improved bioavailability | LCAT, SGMS2, SGMS1 | PTAFR 1976/4885AKT1 1570/4885MTNR1A 1569/4885 |
| US-10739353-B2 | Suppression of cytokine release and cytokine storm | TNF, IL2, IL6 | PTAFR 2280/4885AKT1 838/4885MTNR1A 2567/4885 |
| US-10004687-B2 | Liposomal curcumin for treatment of diseases | LIPA, LPCAT3, LCLAT1 | PTAFR 3986/4885AKT1 2899/4885MTNR1A 2380/4885 |
| US-20080103213-A1 | LIPOSOMAL CURCUMIN FOR TREATMENT OF NEUROFIBROMATOSIS | MEN1, VHL, CALM1 | PTAFR 2740/4885AKT1 1521/4885MTNR1A 615/4885 |
| US-20100316631-A1 | Water Soluble Curcumin-Based Compounds | BAD, TP53, CD14 | PTAFR 2113/4885AKT1 138/4885MTNR1A 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.